These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35334240)

  • 21. Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
    Wimmer K; Hlauschek D; Balic M; Pfeiler G; Greil R; Singer CF; Halper S; Steger G; Suppan C; Gampenrieder SP; Helfgott R; Egle D; Filipits M; Jakesz R; Sölkner L; Fesl C; Gnant M; Fitzal F
    Breast Cancer Res Treat; 2024 Jun; 205(2):227-239. PubMed ID: 38273214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of CTS5 on a Retrospective Cohort of Real-Life Pre- and Postmenopausal Patients Diagnosed With Estrogen Receptor-Positive Breast Cancers: Is It Prognostic?
    Villasco A; Agnelli F; D'Alonzo M; Accomasso F; Sismondi P; Biglia N
    Clin Breast Cancer; 2021 Feb; 21(1):e53-e62. PubMed ID: 32703705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nomogram-Predicted Survival of Breast Cancer Brain Metastasis: a SEER-Based Population Study.
    Xiong Y; Cao H; Zhang Y; Pan Z; Dong S; Wang G; Wang F; Li X
    World Neurosurg; 2019 Aug; 128():e823-e834. PubMed ID: 31096027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 21-Gene Recurrence Score and Survival Outcomes in the Phase III Multicenter TAILORx Clinical Trial.
    Yang SX; Yu J; Wang M
    J Natl Compr Canc Netw; 2024 Jul; 22(6):376-381. PubMed ID: 39019060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and validation of a nomogram to predict overall survival for patients with metastatic renal cell carcinoma.
    Zheng W; Zhu W; Yu S; Li K; Ding Y; Wu Q; Tang Q; Zhao Q; Lu C; Guo C
    BMC Cancer; 2020 Nov; 20(1):1066. PubMed ID: 33148204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nomograms to estimate long-term overall survival and breast cancer-specific survival of patients with luminal breast cancer.
    Sun W; Jiang YZ; Liu YR; Ma D; Shao ZM
    Oncotarget; 2016 Apr; 7(15):20496-506. PubMed ID: 26967253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: A population-based analysis.
    Wu J; Zhang H; Li L; Hu M; Chen L; Xu B; Song Q
    Cancer Commun (Lond); 2020 Jul; 40(7):301-312. PubMed ID: 32558385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index.
    Lee J; Cha C; Ahn SG; Kim D; Park S; Bae SJ; Kim J; Park HS; Park S; Kim SI; Park BW; Jeong J
    Sci Rep; 2020 Oct; 10(1):16850. PubMed ID: 33033359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nomogram for predicting preoperative regional lymph nodes metastasis in patients with metaplastic breast cancer: a SEER population-based study.
    Zhang M; Wang B; Liu N; Wang H; Zhang J; Wu L; Zhao A; Wang L; Zhao X; Yang J
    BMC Cancer; 2021 May; 21(1):565. PubMed ID: 34001061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of late recurrence prediction by gene expression profiles and clinicopathological factors in estrogen receptor-positive breast cancer.
    Kitano S; Tsunashima R; Kato C; Watanabe A; Sota Y; Matsumoto S; Morita M; Sakaguchi K; Naoi Y
    Breast Cancer; 2024 Sep; 31(5):898-908. PubMed ID: 38862868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and validation of a prognostic nomogram for predicting overall survival in patients with primary bladder sarcoma: a SEER-based retrospective study.
    Li S; Liu X; Chen X
    BMC Urol; 2021 Nov; 21(1):162. PubMed ID: 34823525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast.
    Kizy S; Huang JL; Marmor S; Tuttle TM; Hui JYC
    Breast Cancer Res Treat; 2017 Oct; 165(3):757-763. PubMed ID: 28647915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nomogram Update to Predict the High Genomic Risk Breast Cancer by Different Races.
    Wu P; Wu SG; He ZY
    Clin Breast Cancer; 2024 Feb; 24(2):e61-e70.e3. PubMed ID: 38007348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct comparison of three different mathematical models in two independent datasets of EUSOMA certified centers to predict recurrence and survival in estrogen receptor-positive breast cancer: impact on clinical practice.
    Iacuzzo C; Giudici F; Scomersi S; Ceccherini R; Zanconati F; Generali D; Bortul M
    Breast Cancer Res Treat; 2021 Jun; 187(2):455-465. PubMed ID: 33646494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.
    Pece S; Sestak I; Montani F; Tillhon M; Maisonneuve P; Freddi S; Chu K; Colleoni M; Veronesi P; Disalvatore D; Viale G; Buus R; Cuzick J; Dowsett M; Di Fiore PP
    Eur J Cancer; 2022 Mar; 164():52-61. PubMed ID: 35172273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival outcome of adjuvant chemotherapy and high 21-gene recurrence score in early-stage breast cancer.
    Ma SJ; Oladeru OT; Farrugia M; Mikucki M; Iovoli A; Shekher R; Sood A; Singh AK
    Breast J; 2021 Jan; 27(1):27-34. PubMed ID: 33274486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Worse characteristics can predict survival effectively in bilateral primary breast cancer: A competing risk nomogram using the SEER database.
    Shen K; Yao L; Wei J; Luo Z; Yu W; Zhai H; Wang J; Chen L; Fu D
    Cancer Med; 2019 Dec; 8(18):7890-7902. PubMed ID: 31663683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
    Dodson A; Okonji D; Assersohn L; Rigg A; Sheri A; Turner N; Smith I; Parton M; Dowsett M
    Breast Cancer Res Treat; 2018 Feb; 168(1):249-258. PubMed ID: 29128896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A preliminary report of head-to-head comparison of 18-gene-based clinical-genomic model and oncotype DX 21-gene assay for predicting recurrence of early-stage breast cancer.
    Yang PS; Lee YH; Chung CF; Chang YC; Wang MY; Lo C; Tsai LW; Shih KH; Lei J; Yu BL; Cheng SH; Huang CS
    Jpn J Clin Oncol; 2019 Dec; 49(11):1029-1036. PubMed ID: 31287883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.